$8.51
▲ +1.6% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
ADMA: What does Argus have to say about ADMA?
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
ADMA Biologics (ADMA) Faces Class Actions And Probes Over Revenue Allegations
Overview
52-week range
$7.21
$22
9% of range
Avg surprise (last 2)
-2.7%
Avg reaction (last 2)
+0.2%
50% positive
Latest IV / EM
82%
EM ±18.8% · $8 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $0.19 | — | — | +35.7% | -1.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.15 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.15 | $0.14 | +7.1% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $0.14 | $0.16 | -12.5% | — | +2.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.15 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.13 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.08 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.01 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.03 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | $0.16 | $0.15 | +6.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $34M | — | $59M | $55M | $54M | — | $60M | $50M |
| Gross profit | $81M | — | $76M | $67M | $61M | — | $60M | $57M |
| Operating income | $58M | — | $51M | $43M | $35M | — | $40M | $39M |
| Net income | $45M | — | $36M | $34M | $27M | — | $36M | $32M |
| EPS (diluted) | $0.19 | — | $0.15 | $0.14 | $0.11 | — | $0.15 | $0.13 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $138M | $88M | $61M | $90M | $72M | $103M | $87M | $88M |
| Inventory | $222M | $206M | $197M | $191M | $172M | $170M | $172M | $180M |
| Total current assets | $511M | $467M | $403M | $400M | $352M | $331M | $318M | $304M |
| Total assets | $665M | $624M | $569M | $558M | $511M | $489M | $391M | $376M |
| Long-term debt | $194M | $69M | $70M | — | — | $72M | — | — |
| Total liabilities | $275M | $147M | $138M | $160M | $137M | $140M | $159M | $188M |
| Total equity | $390M | $477M | $431M | $398M | $373M | $349M | $232M | $188M |